Navigation Links
Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients

Genzyme Corp. announced top-line data from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic , polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an alarming rise in the incidence of disease, higher numbers of patients with complications and
'"/>




Page: 1 2

Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...vide a bridge to a transplant.Heart failure is cha...cle to pump blood around the body. Till now, it ha...rsible - with the only real cure being a transplan...ce (LVAD) is a mechanical pump which is used to su...
...d that distribution of physician's sample by pharm...n nature of advertisement expenditure falling with...ection 37 of Income Tax Act. The nature of the ad... upon the nature and quality of the article in que...
...t-feed their children for less than three months m...ellectual potential. The results of intelligence t...ldren showed that those who had breast milk for le...t//as those who had been breast-fed for at least s...
...die from smoking, unless they give up now.A survey...shadow what is likely to happen on the mainland in...find that tobacco was the cause of 33% of all male... 30 to 65 age group. When male smokers only are co...
Other Medicine News:
(Date:9/4/2008)...n Schedule with Two Abstracts Accepted for Pre...mber 2008, BRIDGEWATER, N.J., Sept. 4 /PRNewswire...harmaceutical company focused on the treatment of,...ced the appointment of,Peter L. Garrambone, Jr. to...one,s career includes more than 50 pharmaceutical,...
(Date:9/3/2008)...ked. Wrong Children Studied. Wrong,Conclusions Rea... -- A Centers for Disease,Control and Prevention (...between the MMR vaccine and autism. The National A...ng to dispel the growing public concern over a,vac...s concerning design,and methodology., For years, ...
(Date:9/3/2008)...matology Research and Education Foundation,s With...in Detecting, Treating and Und...or the first time during its,unprecedented initiat...merican College of Rheumatology Research and Educa...red from research funded by the Within Our,Reach: ...
(Date:9/3/2008)...al Vascular Disease Awareness Month, CHARLOTTESVI...ceuticals,LLC, a clinical-stage drug-development c... of unmet medical needs, announced today that it h...al trial of its lead drug,candidate trans sodium c...1,on the clinicaltrials.gov Website, is investigat...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Pelosi Floor Statement Urging Override of Presidents Veto of SCHIP 4117 1Pelosi Floor Statement Urging Override of Presidents Veto of SCHIP 4117 2Pelosi Floor Statement Urging Override of Presidents Veto of SCHIP 4117 3Pelosi Floor Statement Urging Override of Presidents Veto of SCHIP 4117 4Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R 26D Summit Conference in Bos 1359 1Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R 26D Summit Conference in Bos 1359 2Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R 26D Summit Conference in Bos 1359 3Catholic Health Association Disappointed by Failure to Override SCHIP Veto 4111 1Shand Morahan 26 Co Inc and AVRECO Launch New Risk Management Program for Midwest Hospitals 4107 1Shand Morahan 26 Co Inc and AVRECO Launch New Risk Management Program for Midwest Hospitals 4107 2
... Study Success in Using Virus Enzyme to Treat Mous...Spray Could Be Used to,Prevent Both Ear Infection ...enn., March 22, 2007 /PRNewswire/ -- Parents might...th a nasal spray of,virus enzymes to prevent them ...on results of a study done in mice by,investigator...
... study shows mesenchymal cells in bone marrow supp...restoring this,critical nutrient when it is deplet..., March 22, 2007 /PRNewswire/ -- The cancer drug,a...acute,lymphoblastic leukemia (ALL) because molecul...unteract the effect of that drug,according to inv...
Other Medicine Technology:Viral Enzyme Recruited in Fight Against Ear Infection 2Viral Enzyme Recruited in Fight Against Ear Infection 3Leukemic Cells Find Safe Haven in Bone Marrow 2Leukemic Cells Find Safe Haven in Bone Marrow 3
...PC-Based Exercise ECG Systems offer clinical featu...dvanced database functionality for paperless stora...he Welch Allyn PCE Exercise ECG software turns any...with its ability to connect with leading EMR syste...
The Quinton Q-Stress Cardiac Stress Monitor combines Quinton algorithms, unique baseline wander and muscle artifact filters, and 8000 samples per second to provide the highest ECG fidelity in the ind
...n non-invasive cardiac diagnosis, the fully featur... stress test system that measures T-wave alternans...rovides a quality control facility, this combines ...ers the signal ensuring outstanding and noise-free...
...Automatic Chart Projector makes refracting easier ...ou program up to 33 charts in any order you wish, ...d room simply by pressing one button each time you...CP-690E's programmable random access gives you the...
Medicine Products: